Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Takuya Hirosawa is active.

Publication


Featured researches published by Takuya Hirosawa.


Hepatology Research | 2014

Full genome analysis of Philippine indigenous subgenotype IA hepatitis A virus strains from Japanese patients with imported acute hepatitis A

Shunji Watanabe; Norio Isoda; Toshiya Ohtake; Takuya Hirosawa; Naoki Morimoto; Kei Aoki; Hiroshi Ohnishi; Masaharu Takahashi; Kentaro Sugano; Hiroaki Okamoto

Hepatitis A virus (HAV) is the most common cause of infectious hepatitis worldwide. Although hepatitis A cases imported from South‐East Asian countries, including the Philippines, have been reported in Japan, the molecular epidemiological data have been limited for these HAV‐endemic countries.


Liver cancer | 2017

Short-Term Results of Laparoscopic Radiofrequency Ablation Using a Multipolar System for Localized Hepatocellular Carcinoma

Naoki Morimoto; Norio Isoda; Yoshinari Takaoka; Takuya Hirosawa; Shunji Watanabe; Toshiya Otake; Kozue Murayama; Takeshi Fujieda; Mamiko Tsukui; Natsumi Miyata; Kohei Ono; Shota Yamaguchi; Hironori Yamamoto

Background and Aim: Multipolar radiofrequency ablation (RFA) is feasible for the treatment of hepatocellular carcinoma (HCC) for which a large ablative area is planned, and it imposes a light physical burden on patients. Multipolar RFA via the percutaneous approach is performed in the majority of cases, but the efficacy of multipolar RFA with a laparoscopic approach has rarely been studied. This study aimed to evaluate the efficacy and safety of multipolar laparoscopic RFA (LRA) for localized HCC over the short term. Methods: From January 2014 to January 2016, 77 consecutive patients with 130 HCCs treated by multipolar LRA were assessed. One to three bipolar needle applicators were inserted under laparoscopic ultrasonography guidance, regardless of tumor location. We intended to achieve parallel insertions and no-touch ablation as much as possible. Results: The median size of the main tumor was 22 mm (range, 10-42 mm). The median follow-up time was 13.6 months (range, 3.1-24.8 months). In all cases, a sufficient ablative area was obtained as planned, without thermal injury of adjacent organs. During the follow-up period, all patients were alive with no local tumor progression, while intrahepatic recurrence distant from the primary site occurred in 7 patients. The 2-year local tumor progression-free survival rate and overall cancer-free survival rate were 100 and 81.6%, respectively. There were no procedural major complications caused prolonging the hospitalization, and all patients were discharged without subjective symptoms 4-7 days after LRA. Conclusions: Multipolar LRA was efficacious in the treatment of localized HCCs by safely achieving a good ablative area.


Internal Medicine | 2019

No Regional Disparities in Sofosbuvir Plus Ribavirin Therapy for HCV Genotype 2 Infection in Tochigi Prefecture and its Vicinity

Takuya Hirosawa; Naoki Morimoto; Kouichi Miura; Toshiyuki Tahara; Toshimitsu Murohisa; Yukishige Okamura; Takashi Sato; Norikatsu Numao; Masato Imai; Shigeo Tano; Kozue Murayama; Hidekazu Kurata; Iwao Ozawa; Yukimura Fukaya; Hiroaki Yoshizumi; Shunji Watanabe; Mamiko Tsukui; Yoshinari Takaoka; Hiroaki Nomoto; Norio Isoda; Hironori Yamamoto

Objective Regional disparities were observed in the outcomes of interferon (IFN)-based therapy for chronic hepatitis C virus (HCV) infection in a Japanese nationwide study. However, whether or not these regional disparities are observed in the outcomes of direct-acting antiviral drugs, including sofosbuvir (SOF) plus ribavirin (RBV) therapy, remains unclear. Methods We conducted a multicenter study to assess the efficacy of SOF plus RBV therapy for HCV genotype 2 infection in Tochigi Prefecture and its vicinity, in which IFN-based therapy yielded a low sustained virologic response (SVR) rate. In addition, we divided Tochigi Prefecture into six regions to examine regional disparities in the SVR. Patients We enrolled patients with chronic HCV genotype 2 infection. Results Of the 583 patients enrolled, 569 (97.6%) completed the treatment, and 566 (97.1%) also complied with post-treatment follow-up for 12 weeks. The overall SVR12 rate was 96.1% by per protocol and 93.7% by intention-to-treat analyses. No marked differences were observed in the SVR12 between subjects ≥65 and <65 years of age. Although large gaps were observed in the characteristics of patients and accessibility to medical resources, there was no significant difference in the SVR12 rate among the six regions in Tochigi Prefecture. Conclusion SOF plus RBV therapy was effective for HCV genotype 2 infection in an area where IFN-based therapy had previously shown unsatisfactory results. In addition, no regional disparities in the SVR12 were observed in Tochigi Prefecture.


Clinical Journal of Gastroenterology | 2014

A case of small hepatocellular carcinoma treated with laparoscopic multipolar radiofrequency ablation with a no-touch ablation procedure

Naoki Morimoto; Norio Isoda; Shunji Watanabe; Toshiya Otake; Takuya Hirosawa; Mamiko Tsukui; Natsumi Miyata; Kozue Murayama; Chihiro Iwashita; Yoshinari Takaoka; Hironori Yamamoto


Kanzo | 2014

Complete response induced by half dose of sorafenib administration in advanced hepatocellular carcinoma with peritoneal dissemination

Naoki Morimoto; Norio Isoda; Toshiya Ootake; Shunji Watanabe; Mamiko Tsukui; Natsumi Miyata; Takuya Hirosawa; Nobuhiko Nagamine; Kentaro Sugano


Clinical Journal of Gastroenterology | 2018

A successful treatment for hepatocellular carcinoma with Osler–Rendu–Weber disease using radiofrequency ablation under laparoscopy

Yoshinari Takaoka; Naoki Morimoto; Kouichi Miura; Hiroaki Nomoto; Kozue Murayama; Takuya Hirosawa; Shunji Watanabe; Takeshi Fujieda; Mamiko Ttsukui; Hirotoshi Kawata; Toshiro Niki; Norio Isoda; Makoto Iijima; Hironori Yamamoto


Liver cancer | 2017

Information of APPLE 2017

Terry M. Therneau; Lewis R. Roberts; Hager A. Ahmed Mohammed; Ju Dong Yang; Nasra H. Giama; Jonggi Choi; Hawa M. Ali; Kristin C. Mara; William S. Harmsen; Russell H. Wiesner; Michael D. Leise; Naoshi Nishida; Satoru Hagiwara; Toshiharu Sakurai; Masatoshi Kudo; Tadaaki Arizumi; Hiroshi Ida; Yoshihiro Sakamoto; Norihiro Kokudo; Yoshikuni Kawaguchi; Keiichi Akita; Guido Torzilli; Naoki Morimoto; Norio Isoda; Yoshinari Takaoka; Takuya Hirosawa; Shunji Watanabe; Toshiya Otake; Kozue Murayama; Mamiko Tsukui


Liver cancer | 2017

The APPLE Association President's Message

Terry M. Therneau; Lewis R. Roberts; Hager A. Ahmed Mohammed; Ju Dong Yang; Nasra H. Giama; Jonggi Choi; Hawa M. Ali; Kristin C. Mara; William S. Harmsen; Russell H. Wiesner; Michael D. Leise; Naoshi Nishida; Satoru Hagiwara; Toshiharu Sakurai; Masatoshi Kudo; Tadaaki Arizumi; Hiroshi Ida; Yoshihiro Sakamoto; Norihiro Kokudo; Yoshikuni Kawaguchi; Keiichi Akita; Guido Torzilli; Naoki Morimoto; Norio Isoda; Yoshinari Takaoka; Takuya Hirosawa; Shunji Watanabe; Toshiya Otake; Kozue Murayama; Mamiko Tsukui


Kanzo | 2017

A case of hepatic sarcoidosis complicated by portal hypertension

Takuya Hirosawa; Naoki Morimoto; Koichi Miura; Shunji Watanabe; Mamiko Tsukui; Kozue Murayama; Yoshinari Takaoka; Hiroaki Nomoto; Takeo Nakaya; Hisashi Oshiro; Norio Isoda; Hironori Yamamoto


Kanzo | 2016

Drug-eluting beads transarterial chemoembolization is feasible treatment option for advanced hepatocellular carcinoma with portal vein tumor thrombosis

Shunji Watanabe; Naoki Morimoto; Toshiya Otake; Mamiko Tsukui; Natsumi Miyata; Takuya Hirosawa; Kozue Murayama; Yoshinari Takaoka; Chihiro Iwashita; Hiroyasu Nakamura; Norio Isoda; Hideharu Sugimoto; Hironori Yamamoto

Collaboration


Dive into the Takuya Hirosawa's collaboration.

Top Co-Authors

Avatar

Naoki Morimoto

Jichi Medical University

View shared research outputs
Top Co-Authors

Avatar

Norio Isoda

Jichi Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mamiko Tsukui

Jichi Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kozue Murayama

Jichi Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Toshiya Otake

Jichi Medical University

View shared research outputs
Top Co-Authors

Avatar

Natsumi Miyata

Jichi Medical University

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge